A randomized trial of pancreatic stent placement and NSAIDs to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis

A randomized trial of pancreatic stent placement and NSAIDs to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis - A randomized trial of pancreatic stent placement and NSAIDs to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031705

Enrollment

300

Registered

2018-03-14

Start date

2015-08-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

post-endoscopic retrograde cholangiopancreatography pancreatitis

Interventions

50mmg of rectal non-steroidal anti-inflamation drugs,30 min before ERCP Pancreatic duct stent

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: all patients who scheduled to undergo ERCP are included.

Exclusion criteria

Exclusion criteria: acute pancreatitis,chronic pancreatitis with acute painful exacerbation,peptic ulcer,rectal disease,aspirin-induced asthma,NSAIDs during the preceding 1 week,hypersensitivity to NSAIDs,severe renal dysfunction,pregnant,breast-feeding,inability to provide written informed consent

Design outcomes

Primary

Measure	Time frame
The occurrence of post ERCP pancreatitis	—

Countries

Japan

Contacts

Public ContactTakao Kato

Hyogo prefectural Awaji Medical Center Department of Gatroenteterology

takao.k@juno.ocn.ne.jp0799-22-1200

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026